82
Participants
Start Date
December 2, 2014
Primary Completion Date
December 15, 2016
Study Completion Date
December 15, 2016
Ipilimumab
Local Institution, St Leonards
Local Institution, Wahroonga
Local Institution, Parkville
Local Institution, Marseille
Urologische Praxis, Rostock
George Washington University Medical Center, Washington D.C.
Local Institution, Milan
Virginia Cancer Institute, Richmond
Baptist Cancer Institute, Jacksonville
Local Institution, Rennes
North Mississippi Med Center, Tupelo
Universitaetsklinikum Magdeburg, Magdeburg
Local Institution, Seville
Dgu Urologie, Wuppertal
Local Institution, Saint-Herblain
Local Institution, Valencia
Urologische Gemeinschaftspraxis Dres Stammel U. Garcia, Wesel
Universitaetsklinikum Aachen, Aachen
Local Institution, Clermont-Ferrand
Cancer Center Of Kansas, Wichita
Nebraska Cancer Specialists, Omaha
Universitaetsklinikum Mannheim, Mannheim
Uniklinik Heidelberg, Heidelberg
Texas Oncology, Houston
Istituto Nazionale Tumori Fondazione Pascale, Napoli
Klinikum rechts der Isar der TU, München
San Francisco Oncology Associates, San Francisco
Local Institution, Villejuif
Local Institution, Marktredwitz
Northwest Cancer Specialists, Pc, Tualatin
Providence Portland Medical Center, Portland
Local Institution, Viña del Mar
University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh
Local Institution, Recoleta
Local Institution, Santiago
Local Institution, Poitiers
Universitaetsklinikum Jena, Jena
Local Institution, Amsterdam
Local Institution, Barcelona
Local Institution, Hospitalet de Llobregat - Barcelona
Local Institution, Glasgow
Local Institution, Nottingham
Local Institution, Guildford
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY